Manila Times Business
Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours
ORION CORPORATION PRESS RELEASE 30 MAY 2026 at 21:30 EEST Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours Data presented at 2026 ASCO® Annual Meeting show ODM-212 was well tolerated, with proteinuria being the most common treatment related adverse event (TRAE)ODM-212 showed early efficacy in Hippo pathway dysregulated tumours, such as mesothelioma and EHE (epithelioid hemangioendothelioma)A clinical development
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Typhoon Domeng less likely to make landfall, to exit PAR Monday —Pagasa
1h ago
National Champions are Honoured at the Closing Ceremony of the Skills Canada National Competition 2026, in Toronto
2h ago
Take Your Shot & Make Your Moment: OPPO Ignites Football Culture with Technology at the UEFA Champions League Final
2h ago
ThinkCareBelieve: Week 71 of the Trump Administration 2.0
3h ago